Acute promyelocytic leukemia current treatment algorithms

Musa Yilmaz,Hagop Kantarjian,Farhad Ravandi
DOI: https://doi.org/10.1038/s41408-021-00514-3
IF: 9.812
2021-06-01
Blood Cancer Journal
Abstract:Abstract In 1957, Hillestad et al. defined acute promyelocytic leukemia (APL) for the first time in the literature as a distinct type of acute myeloid leukemia (AML) with a “rapid downhill course” characterized with a severe bleeding tendency. APL, accounting for 10–15% of the newly diagnosed AML cases, results from a balanced translocation, t (15;17) (q22;q12-21), which leads to the fusion of the promyelocytic leukemia ( PML ) gene with the retinoic acid receptor alpha ( RARA ) gene. The PML–RARA fusion oncoprotein induces leukemia by blocking normal myeloid differentiation. Before using anthracyclines in APL therapy in 1973, no effective treatment was available. In the mid-1980s, all-trans retinoic acid (ATRA) monotherapy was used with high response rates, but response durations were short. Later, the development of ATRA, chemotherapy, and arsenic trioxide combinations turned APL into a highly curable malignancy. In this review, we summarize the evolution of APL therapy, focusing on key milestones that led to the standard-of-care APL therapy available today and discuss treatment algorithms and management tips to minimize induction mortality.
oncology,hematology
What problem does this paper attempt to address?